In Silico Trials

Reduce, Refine, and partially Replace Human and Animal Trials

Computational modelling & simulations

  • carefully engineer medical product innovations,

  • explicitly optimise clinical outcomes, and

  • thoroughly assess side effects before being marketed

Benefits

  • Better Patient Outcomes

  • Less Risk to Patients

  • Better Device Designs

  • Fail Faster and Earlier

  • Reduce R&D Costs

  • Reduced Animal Harm

Trials on Real vs In Silico Patients - an exemplar

A typical Randomised Controlled Trial (RCT) of a cardiovascular device can take 6 to 8 years from design to publication, and cost £40-80m. Such a device can go to market with testing on less than 500 patients

We use cookies to improve your experience and to help us understand how you use our site. Please refer to our cookie notice and privacy statement for more information regarding cookies and other third-party tracking that may be enabled.

Intuit Mailchimp logo
Twitter icon
Website icon
Email icon
LinkedIn icon

© 2022-2023 InSilicoUK Network